Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.61 |
| ▸ | RXRA | P19793 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL5499351 | 0.96 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AHPGDMAPT | |
| Bicarbonate SCHEMBL5499350 | 0.96 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AHPGDMAPT | |
| SCHEMBL2188210 | 0.94 | SMPD1 (0.76) | SMN1; SMN2NPC1RAB9AHPGDMAPT | |
| SCHEMBL3245222 | 0.94 | SMPD1 (0.67) | SMN1; SMN2NPC1RAB9AHPGDMAPT | |
| SCHEMBL1781433 | 0.92 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AHPGDMAPT | |
| SCHEMBL11286951 | 0.91 | NPC1 (0.78) | SMN1; SMN2NPC1RAB9AHPGDMAPT | |
| SCHEMBL2087641 | 0.90 | NPC1 (0.71) | SMN1; SMN2NPC1RAB9AHPGDMAPT | |
| Bicarbonate SCHEMBL5504807 | 0.90 | SMPD1 (0.62) | SMN1; SMN2NPC1RAB9AHPGDMAPT | |
| Bicarbonate SCHEMBL5504809 | 0.90 | SMPD1 (0.62) | SMN1; SMN2NPC1RAB9AHPGDMAPT | |
| SCHEMBL18660058 | 0.89 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102603718-B | Synthesis method of cediranib | CHEMPROSPECT PHARMTECH CO LTD | 2014-01-29 | — | — | CN | claimed |
| CN-102603718-A | Synthesis method of cediranib | WUHAN CATALIBI UNI PHARMA INC LTD | 2012-07-25 | — | — | CN | claimed |
| US-20240067652-A1 | METHOD OF PREPARING INDOLINOBENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067652-A1 | METHOD OF PREPARING INDOLINOBENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| CN-111253385-B | Heterocyclic compound, preparation method and application | 遵义医科大学珠海校区 | 2023-11-24 | — | — | CN | disclosed |
| US-11760759-B2 | Process for preparing substituted indolines | IMMUNOGEN, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760759-B2 | Process for preparing substituted indolines | IMMUNOGEN, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| EP-2956138-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS INC (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3590924-B1 | NOVEL ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-20210292329-A1 | METHODS OF PREPARING INDOLINOBENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-09-23 | — | — | US | disclosed |
| US-10968228-B2 | Methods of preparing substituted 12a,13-dihydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indoles | IMMUNOGEN, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| CN-1165532-C | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | ���Ͽع�����˾ | 2004-09-08 | — | — | CN | disclosed |
| CN-1144786-C | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | 谷 | 2004-04-07 | — | — | CN | disclosed |
| US-6689772-B1 | ANTINEOPLASTIC AGENTS; OSTEOPOROSIS; POLYCYSTIC KIDNEY DISEASE; ANTIVIRAL AGENTS | WYETH | 2004-02-10 | — | — | US | disclosed |
| US-6521618-B2 | Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease | WYETH | 2003-02-18 | — | — | US | disclosed |
| EP-1268431-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-28 | — | — | US | disclosed |
| CN-1320121-A | Substituted 3-cyanoquinolines as protein tyrosine kinase inhibitors | AMERICAN CYANAMID CO (US) | 2001-10-31 | — | — | CN | disclosed |
| CN-1320118-A | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | AMERICAN CYANAMID CO (US) | 2001-10-31 | — | — | CN | disclosed |
| WO-2001072711-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067652-A1 | METHOD OF PREPARING INDOLINOBENZODIAZEPINE DERIVATIVES | HTR3B, HTR3C, HTR3D | SMN1; SMN2 2332/4885NPC1 3183/4885RAB9A 1350/4885 |
| US-10968228-B2 | Methods of preparing substituted 12a,13-dihydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indoles | TPH1, HTR1B, HTR1A | SMN1; SMN2 2744/4885NPC1 2236/4885RAB9A 1795/4885 |
| US-20210292329-A1 | METHODS OF PREPARING INDOLINOBENZODIAZEPINE DERIVATIVES | HTR3C, HTR3B, HTR3D | SMN1; SMN2 2248/4885NPC1 2992/4885RAB9A 1340/4885 |
| US-11760759-B2 | Process for preparing substituted indolines | IDO2, IDO1, INMT | SMN1; SMN2 2184/4885NPC1 4692/4885RAB9A 1864/4885 |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | SMN1; SMN2 4511/4885NPC1 653/4885RAB9A 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.